leflunomide + diclofenac sodium

**Leflunomide + diclofenac sodium** is a combination drug designed for the treatment of active rheumatoid arthritis in adults and for the temporary relief of arthritis pain. Leflunomide is an immunomodulatory agent classified as a disease-modifying anti-rheumatic drug (DMARD) that inhibits pyrimidine synthesis, suppressing the proliferation of activated lymphocytes and thereby reducing inflammation. Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis to alleviate pain and inflammation. The combination aims to address both the underlying autoimmune components (leflunomide) and provide symptomatic relief (diclofenac sodium). This combination is available as a gel kit and is not FDA-approved as of October 2025[1].

Brand names

Lefluniclo

Other names

leflunomide and diclofenac sodium gel kit